University of Kentucky Markey Cancer Center

What University of Kentucky Markey Cancer Center does

The University of Kentucky Markey Cancer Center is an NCI-designated academic cancer center operated within the University of Kentucky HealthCare (UK HealthCare) public state-university system, headquartered in Lexington, Kentucky. The center delivers comprehensive cancer care spanning medical, surgical, and radiation oncology, hematology, and palliative services, organized around specialized multidisciplinary clinics (breast, head and neck, hematology, precision medicine, acute treatment, and others). It maintains a 9,000-person UK HealthCare workforce, 80+ specialized clinics, and 140+ community outreach programs, including rural Federally Qualified Health Center sites in Hazard and Hindman that extend its catchment into Appalachian Kentucky.

Markey's distinguishing capabilities are its NCI designation (held since 2013), access to NCI-sponsored clinical trials, advanced cellular therapy including emergency-use CAR-T for solid tumors with brain metastases, and a precision medicine program supported by a Genomics Core Laboratory. Active clinical research includes a Phase 2 trial of ArtemiCafe Decaf (Artemisia annua-infused decaffeinated coffee) as prostate cancer maintenance therapy in partnership with ArtemiLife, and translational research such as the discovery of the TRIM28/LDHA pathway driving prostate cancer bone metastases. The Beyond ASK quality improvement initiative, co-developed with the American College of Surgeons Commission on Cancer, raised smoking cessation assistance delivery rates from 48% to 67.5% across 324 enrolled cancer programs covering more than 446,000 newly diagnosed patients.

Revenue is generated primarily through clinical care billing (hospital-based clinic with separate physician and facility charges), federal 340B drug pricing program participation, research grants (including a renewed $360,000 American Cancer Society Institutional Research Grant funding nine pilot awards over three years), and philanthropy. The center is funded through university allocations, NCI Cancer Center Support Grant funding, clinical revenue, and philanthropy, with no venture or private equity ownership. It holds Joint Commission accreditation, Magnet Status nursing credentialing, and is the highest-ranked hospital in Kentucky per U.S. News & World Report.

Name

University of Kentucky Markey Cancer Center

Legal name

University of Kentucky

Website

https://ukhealthcare.uky.edu

Company type

Public

Founded year

2013

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

The University of Kentucky Markey Cancer Center is an NCI-designated academic cancer center within UK HealthCare that delivers comprehensive oncology treatment, clinical trials, and translational research to patients across Kentucky and Appalachia, with particular strength in cellular therapy and rural outreach.

Ownership category

akta.pro rank

Product category

Cancer Treatment Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (622310), General Medical and Surgical Hospitals (62211), Diagnostic Imaging Centers (621512), Health Care and Social Assistance (62)

SIC

Services-Health Services (8000), Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro primary industry

Oncology & Cancer Specialty Hospitals (HLAFAHAC)

akta.pro secondary industries

Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI), Medical Oncology (HLAKAFAB), Radiation Oncology (HLAKAFAC), Surgical Oncology (HLAKAFAG), Thoracic (Lung) Oncology (HLAKAFAL), Hospital-Integrated Cancer Centers (Acute Oncology Programs) (HLAFAAAM)

Keywords

• Cancer treatment services
• Oncology clinical trials
• Precision medicine oncology
• Radiation oncology services
• NCI cancer care

Headquarters

HQ city

Lexington

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure

Revenue model

1. American Cancer Society Institutional Research Grant: $360,000 grant funding nine pilot awards over three years to support early-stage cancer research across various disciplines
2. Clinical Care Services: Healthcare services billing for cancer treatment, diagnostic imaging, chemotherapy, radiation oncology, and surgical services. Hospital-based clinic billing structure with separate physician and facility charges.
3. 340B Drug Pricing Program: Federal program providing discounted outpatient drugs from manufacturers, allowing UK HealthCare to provide care to more eligible patients and expand services

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Core offering

University of Kentucky Markey Cancer Center is a National Cancer Institute (NCI)-designated comprehensive cancer center that provides multidisciplinary cancer care including medical oncology, surgical oncology, radiation oncology, hematology, diagnostic imaging, and palliative care. It offers patients access to clinical trials and advanced treatments (such as CAR-T cell therapy) not generally available at other hospitals, alongside cancer screening, smoking cessation integration, and survivorship programs.

Product overview

University of Kentucky Markey Cancer Center is a single unified cancer care institution that operates as part of UK HealthCare. It provides comprehensive cancer treatment services including medical oncology, surgical oncology, radiation oncology, and hematology. The center offers access to National Cancer Institute-designated clinical trials and advanced treatments not generally available elsewhere. Services span cancer types including breast cancer, prostate cancer, head and neck cancer, and blood cancers, with related programs including smoking cessation integration into cancer care and cancer screening programs.

Differentiator

Problem solved

Functional benefit

Products and services

• UK Markey Cancer Center Comprehensive Cancer Care An NCI-designated comprehensive cancer center providing medical oncology, surgical oncology, radiation oncology, hematology, and supportive care for all cancer types for patients across Kentucky and the region.
• Cancer Clinical Trials

Quantifiable outcome

• Quitting smoking within six months of cancer diagnosis can improve median survival by nearly four years
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core.

• ArtemiLifecoreStrategic or Co-development Partner · 1 August 2023Phase 2 clinical trial collaboration for ArtemiCafe Decaf (decaffeinated coffee infused with Artemisia annua) as prostate cancer maintenance therapy. Trial investigates whether daily consumption can reduce or stabilize rising PSA levels in men with biochemical recurrence of prostate cancer. Enrollment began August 2023 with 24-week treatment duration of four cups daily.
• American Cancer Society (ACS)coreStrategic or Co-development Partner · 8 December 2022ACS Institutional Research Grant (IRG) renewal providing $360,000 to fund nine pilot awards over three years to promote early-stage cancer research across various disciplines at the Markey Cancer Center.
• American College of Surgeons Commission on CancercoreStrategic or Co-development PartnerCollaborative development of Beyond ASK quality improvement initiative for smoking cessation assistance integration into standard cancer care. Initiative enrolled 324 cancer programs and covered over 446,000 newly diagnosed cancer patients.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Regional players

• St. Claire HealthCare (Morehead, KY): Regional Kentucky community health system that refers advanced cancer cases out to tertiary centers. Comparable because it sits in Markey's rural referral network and competes for lower-acuity oncology volume in eastern Kentucky.
• Baptist Health Lexington: Regional non-academic health system with significant Lexington, KY presence. Comparable as a competing community cancer care provider in Markey's immediate primary service area, though not NCI-designated and without the academic research and clinical trial infrastructure.

Direct peers

• The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital: NCI-designated academic cancer center integrated into a public state university health system with an inpatient cancer hospital. Directly comparable to Markey because both are public university NCI cancer hospitals serving the broader Appalachian/Midwest region with research-driven oncology programs and academic medical center infrastructure.
• University of Cincinnati Cancer Center: NCI-designated comprehensive cancer center operating within a public, mid-sized academic medical system in an adjacent Ohio/Kentucky region. Comparable because both institutions are state-university-affiliated NCI cancer centers treating Appalachian-region patient populations with community outreach, clinical trials, and multidisciplinary oncology teams.
• Vanderbilt-Ingram Cancer Center: Another NCI-designated comprehensive cancer center housed within an academic medical center in the U.S. Southeast. Directly comparable because both deliver multispecialty oncology care, run investigator-initiated clinical trials, hold NCI Comprehensive Cancer Center status, and serve regional catchments with rural outreach — Markey in Kentucky, Vanderbilt-Ingram in Tennessee.
• Indiana University Melvin and Bren Simon Comprehensive Cancer Center: NCI-designated cancer center at a public research university in an adjacent Midwestern state. Comparable as a state-university NCI cancer center with similar mix of academic oncology services, clinical trials, and rural-state catchment.
• Winship Cancer Institute of Emory University: NCI-designated comprehensive cancer center within a leading academic medical system. Comparable to Markey in terms of NCI designation, comprehensive cancer service line (medical/surgical/radiation oncology), and trial sponsorship portfolio, though larger in scale and catchment.

Broad incumbents

• MD Anderson Cancer Center: The largest standalone NCI-designated cancer center in the U.S. and a global destination for advanced cancer treatment. Comparable because it offers the same category of advanced oncology care and clinical trials Markey does (including CAR-T and precision medicine), but operates at a much larger national/international scale and serves as the volume ceiling for regional NCI centers like Markey.
• Memorial Sloan Kettering Cancer Center: Premier NCI-designated comprehensive cancer center with a leading CAR-T, Phase 1 trials, and rare-tumor portfolio. Comparable to Markey in the same clinical categories, though MSK operates at far greater scale and acts as a national/international referral destination that caps referral pricing power for regional NCI centers.
• Siteman Cancer Center (Washington University in St. Louis): NCI-designated comprehensive cancer center within a private research university medical center. Comparable in NCI services mix including CAR-T and precision oncology, with a slightly broader geography overlapping Markey's referral region.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/uk_healthcare
• YouTubeyoutube.com/UKHealthCare
• Facebookfacebook.com/UKHealthCare
• LinkedInlinkedin.com/company/universityofkentucky

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries9 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about University of Kentucky Markey Cancer Center